AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03357029 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GammaCore Device
Description: GammaCore will be administered using a handheld device the size of a mobile phone, which consists of a battery powered portable stimulator with a digital control user interface that controls the stimulation amplitude and two steel contact electrodes.
Study NCT03357029 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Device
Description: Sham device will be administered using a handheld device the size of a mobile phone, which consists of a battery powered portable stimulator with a digital control user interface that controls the stimulation amplitude and two steel contact electrodes. The sham device is identical in appearance, weight, visual and audible feedback, and user application and control but did not deliver electrical stimulations.
Study NCT03790813 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Intervention 1
Description: Ki-67 and Oncotype DX® will be performed on the baseline core biopsy specimen prior to initiation of neoadjuvant systemic therapy.
Study NCT03790813 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Intervention 2
Description: MRI will be performed prior to initiation of neoadjuvant systemic therapy and at the end of treatment.
Study NCT04431843 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Spirulina maxima extract
Description: once a day for 2 p.o., after breakfast and dinner(1.52 g/day, Spirulina maxima extract for 1.5 g/day) for 12 week
Study NCT04431843 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once a day for 2 p.o., after breakfast and dinner(1.52 g/day, Spirulina maxima extract for 0 g/day) for 12 week
Study NCT02365610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GWP42006
Study NCT02365610 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Control
Study NCT04220320 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Vaginal examination.
Description: Cervical properties as evaluated by a vaginal examination.
Study NCT04220320 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Transvaginal sonography.
Description: Cervical length as evaluated by a transvaginal sonography.
Study NCT00523562 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diet intervention
Description: controlled hypercaloric high fructose, high fat, or high fat/high protein diet
Study NCT04639375 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccinated with polio vaccine (IPV)
Description: poliovirus vaccine (IPV) manufactured by Sanofi Pasteur for distribution in the United States
Study NCT03118635 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Physical activity programming in accordance with the SPARK - After School curriculum as well as engaging activities provided by local community partners. The intervention proceeded the SFSP lunch meal service, so that children received approximately three hours of physical activity programming daily.
Study NCT00972868 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A unidirectional face mask (Modified 'Respironics PerformaTrak' Mask)
Description: The regular face mask will be replaced with the study mask and patients will receive NPPV via the study mask for 30 min. The study mask insures a unidirectional breathing pattern, in through the nose and out through the mouth or in through the mouth and out through the nose. The sequence of these two breathing patterns with opposite flow direction will be chosen randomly. Each will be applied for 30 min with data collected during and at the end of the period.
Study NCT02470585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Description: Capsules for oral administration
Study NCT02470585 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Administered by intravenous infusion, either 80 mg/m² of body-surface area (BSA) on Days 1, 8, and 15 of each 21-day cycle (weekly dosing), or 175 mg/m² of BSA on Day 1 of each 21-day cycle (3-week dosing).
Study NCT01776112 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Standard treatment and participation in the sports program (cycling) including cognitive training, 3 sessions cycling (30 min. each) per week for 3 months and 2 sessions Cogpack per week for the last 6 weeks.
Study NCT02033850 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention Process Training-II
Description: Rehabilitation of attention using the Attention Process Training-II
Study NCT02470585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Administered by intravenous infusion, either 80 mg/m² of body-surface area (BSA) on Days 1, 8, and 15 of each 21-day cycle (weekly dosing), or 175 mg/m² of BSA on Day 1 of each 21-day cycle (3-week dosing).
Study NCT02470585 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Administered by intravenous infusion at an area under the curve (AUC) of 6 mg/mL/min every 3 weeks.
Study NCT02470585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Administered by intravenous infusion at an area under the curve (AUC) of 6 mg/mL/min every 3 weeks.
Study NCT02470585 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to Veliparib
Description: Capsules for oral administration
Study NCT02470585 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo to Veliparib
Description: Capsules for oral administration
Study NCT03221465 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-monitoring of physical activity with incentives
Description: Participants are given a pedometer (e.g. Misfit brand wrist pedometer) to allow self-monitoring of physical activity and receive financial incentives. Participants also answer two health questions a week for 12 weeks.
Study NCT03221465 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care and self-monitoring of physical activity
Description: Participants simply given a pedometer (e.g. Misfit brand wrist pedometer) with no other intervention to allow self-monitoring of physical activity.
Study NCT02991898 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infusion of Treg
Description: Allopurinol on day -7 to day 0 Cyclophosphamide 50 mg/kg IV over 2 hours on day -6 Fludarabine 30mg/m2 IV over 1 hour on day -6, -5, -4, -3, and -2 Total Body Irradiation 200 cGy as a single dose~Sirolimus 8mg-12mg oral loading dose followed by single dose 4mg/day. Levels are to be monitored 3 times/week in the first week, weekly until day +60, and as clinically indicated until day +100 post-transplantation.~Mycophenolate Mofetil (MMF) 3 gram/day IV/PO divided in 2 or 3 doses. Stop MMF at day +30 or 7 days after neutrophil recovery, whichever day is later, if no acute GVHD.~DUCBT followed Tregs - double umbilical cord blood transplant (FIRST) followed by the Treg cell infusion (SECOND) no sooner than 1 hour, but within 24 hours after the 2nd cord blood infusion.
Study NCT03263988 — intervention group
Intervention type: DEVICE
Intervention: ConCardiac
Description: All patients receive a piezocapacitative-interlayer-technology hemodynamic measurement by ConCardiac device (SectorCon GmbH, Berlin, Germany).
Study NCT01551654 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Transcutaneous Electrical Nerve Stimulation (ITO Company )
Description: A mobile small machine for nerve stimulation
Study NCT01551654 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Nerve Stimulation (ITO Company )
Description: A mobile small machine for nerve stimulation
Study NCT03267979 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Video-pupillometer
Description: Video-pupillometer will be performed. In this study data will be collected and analyzed.
Study NCT03267979 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Electrocardiogram
Description: Electrocardiogram will be performed. In this study data will be collected and analyzed.
Study NCT03548896 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Post extraction socket
Description: \*\*Dental implant will be placed 3 months after tooth extraction
Study NCT00819156 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: degarelix
Description: Degarelix was given as subcutaneous injections.
Study NCT01162252 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness-Based Stress Reduction
Description: The standardized Mindfulness-Based Stress Reduction (MBSR) program is the primary training tool used to enhance mindfulness. The eight-week-long MBSR program is designed to teach subjects how to develop their inner resources in the service of taking better care of themselves. MBSR training includes the learning and refining of a range of skills aimed at increasing relaxation and awareness of physical experiences and sensations related to physical symptoms, emotions, and thoughts. Special emphasis is placed on movement, meditation, and breathing.
Study NCT01162252 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Living Well
Description: The Living Well (LW) program involves a series of informational presentations and group discussions on a variety of topics related to the promotion of health and well-being. The 8-week program is designed to provide participants with knowledge about ways to improve their physical and emotional health as a complement to traditional medical treatments.
Study NCT04224103 — intervention group
Intervention type: DRUG
Intervention: Inhaled nitric oxide
Description: Stage 1: Patients in whom VA ECMO is being initiated will be invited to participate. Hemodynamic, echocardiographic, and biochemical parameters will be measured immediately prior to iNO administration, and thirty minutes after initiation. After six hours, hemodynamic, echocardiographic, and biochemical parameters will be re-assessed after which iNO will be weaned. All parameters will be re-evaluated 30 minutes after iNO discontinuation.~Stage 2: iNO will be re-initiated 30 minutes prior to the ECMO weaning trial. Hemodynamic, echocardiographic, and biochemical parameter will be recorded immediately prior to iNO administration and then at 30 minutes prior to the ECMO weaning trial. When ECMO weaning is unsuccessful, these parameters will be recorded immediately prior to re-initiation of full flow VA ECMO and 30 minutes thereafter. If successful, data will be collected after the wean and after iNO discontinuation.
Study NCT01776112 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: TableSoccer
Description: Standard treatment and participation in an activity without physical improvement as placebo condition (table football in groups of 4), but including cognitive training, 3 sessions (30 min. each) per week for 3 months and 2 sessions Cogpack per week for the last 6 weeks.
Study NCT01155271 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation
Description: 12 weeks : 3 sessions per week (2 supervised sessions and 1 session at home)~1 technical visit and 1 nursing visit every two months at home for the CPAP
Study NCT01281865 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diagnostic laboratory biomarker analysis
Description: Correlative studies
Study NCT01281865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: Given PO
Study NCT01281865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Description: Given PO
Study NCT00585143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-335
Description: 45 mg once daily for 10 consecutive days
Study NCT03873298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide
Description: Inhaled nitric oxide delivered through a pulsatile nitric oxide drug delivery system
Study NCT02949050 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: subcutaneous allergen immunotherapy (SCIT)
Description: 20 patients who (prior to study enrollment and initiation) completed more than 1 year of timothy grass SCIT vs. 20 control patients who underwent corn pollen exposure for for greater than one year during the same prestudy time interval. Efficacy will be assessed by analyses of symptom score surveys and quality of life surveys.
Study NCT00585143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: 10 mg once daily for 10 days
Study NCT02508181 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: I-gel
Description: supraglottic airway device without cuff
Study NCT02508181 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LMA Supreme
Description: supraglottic airway device with cuff
Study NCT02949050 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCIT
Description: Treatment group consists of patients who completed > 1 year of SCIT while control group patients did not undergo SCIT
Study NCT01480583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GRN1005
Description: 550 mg/m2 IV every 3 weeks
Study NCT02295384 — intervention group
Intervention type: OTHER
Intervention: Retrospective Audit
Description: Retrospective Audit
Study NCT01480583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: 2 mg/kg IV every week or 6 mg/kg IV every 3 weeks per investigator choice
Study NCT01480583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-FLT
Description: 5 mCi of 18F-FLT IV during Screening and during Cycle 1
Study NCT01218373 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HOMESWEETHOME Services
Description: Monitoring and alarm handling services. eInclusion services. Domotic services. Daily scheduler. Navigation services. Cognitive training services. Non-technology based services.
Study NCT01218373 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: No HOMESWEETHOME services installed
Description: Normal care and healthcare without HOMESWEETHOME services.
Study NCT01147159 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Extracts of allergens
Description: Skin prick test of extracts of allergens in 4 tenfold dilutions. Assessment wheal size after 15 minutes
Study NCT03144128 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: 5,000IU vitamin D given daily for 12 weeks
Study NCT03144128 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules given daily for 12 weeks
Study NCT02434549 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dysport®
Description: Intramuscular injections in spastic muscle with regional muscle-related pain
Study NCT02434549 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Intramuscular injections in spastic muscle with regional muscle-related pain
Study NCT01130909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6765
Description: 75 mg
Study NCT01130909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6765
Description: 150 mg
Study NCT01130909 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: 0.5 mg/kg
Study NCT02621060 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: 1200 mg per day for three months
Study NCT02621060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorogenic acid
Description: Chologenic acid: 1200 mg per day for three months
Study NCT00573612 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Attention Control Counseling
Description: Subjects will receive educational-based telephone counseling regarding fibromyalgia.
Study NCT01130909 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 125 mL sterile NaCl 0.9%
Study NCT01800331 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text2bHealthy
Description: The intervention group uses handheld computers to keep track of their lifestyle behaviours and they will receive feedback on thier progress and tips (Text2bHealthy)
Study NCT02689414 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote ischaemic preconditioning
Description: Ischaemia is achieved by using a blood pressure cuff on an arm by raising the cuff pressure to 200 mm Hg or to a value that is 20 mm Hg greater than the patient's systolic blood pressure - if the patient's systolic blood pressure is more than 180 mm Hg. The intervention starts simultaneously with the induction of anaesthesia or a few minutes earlier.
Study NCT02689414 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Control to RIPC
Description: Venous pressure is achieved by using a blood pressure cuff on an arm by raising the cuff pressure to 10-20 mm Hg. The intervention starts simultaneously with the induction of anaesthesia or a few minutes earlier.
Study NCT01127672 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: platelet rich plasma
Description: 30 ml of a patient's own blood will be collected via blood draw, maintaining sterile technique. This will then be spun down using a Magellan Autologous Platelet Separator System, yielding platelet rich plasma (PRP).~Under sterile conditions, patients will receive a 3 cc PRP injection (consisting of their own PRP) with 1 cc of 2% lidocaine into the origin of the plantar fascia, administered by an orthopedic surgeon.~This will be done using a plantar approach. A peppering technique spreading in clockwise manner will be used to achieve a more expansive zone of delivery, with a maximum of 10 passes through the fascia itself.~The patient will be monitored for 10 minutes in clinic for adverse reactions.
Study NCT01127672 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: corticosteroid injection
Description: Under sterile conditions, patients will receive a 4 cc injection consisting of 2 cc Celestone Soluspan (6mg/ml) and 2 cc of 1% lidocaine into the origin of the plantar fascia, administered by an orthopedic surgeon.~This will be done using a plantar approach. A peppering technique spreading in clockwise manner will be used to achieve a more expansive zone of delivery, with a maximum of 10 passes through the fascia itself.~The patient will be monitored for 10 minutes in clinic for adverse reactions.
Study NCT01447498 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Screening for risk factors for ulcer bleeding
Description: Following PCI the patients fill out a questionnaire to assess the risk factors for ulcer bleeding.We randomise between:~1. screening and risk assessment~2. control group~All screened patients, who fulfil the criteria for having a moderate to high risk of ulcer bleeding will be sent written information about risk factors and the purpose of the PPI prophylaxis. They will be recommended PPI prophylaxis (Pantoprazole), as long as they are being treated with low-dose aspirin and clopidogrel.~Patients in the screening group, who are already on PPI treatment is recommended to change to Pantoprazole.~Definition of risk of ulcer bleeding: The table below will be used for screening. Patients scoring ≥ 2 points will receive PPI prophylaxis.~points: Age: \< 60: 0; 60-69: 1; 70-79: 2; >=80: 3 ___ Dyspepsia: 1 ___ Uncomplicated ulcer: 2 ___ Complicated ulcer 3 ___ NSAID 2 ___ Steroids 2 ___ SSRI 2 ___ Anticoagulant Tx 2 ___
Study NCT00828802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide, Decitabine
Description: Decitabine 20mg/m2 over one hour IV for 5 days, with cycles repeated every 28 days. Lenalidomide given orally on Days 1-21 followed by 7 days of rest at various dose escalated cohorts (5 mg, 10mg, 15mg, 20 mg, 25 mg)
Study NCT03423446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telotristat Ethyl
Description: Telotristat ethyl (TE) 250 mg (1 x 250-mg tablet), single dose
Study NCT01621256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ancrod
Description: Day 1: Intravenous infusion; Days 2, 4, and 6: Subcutaneous injections
Study NCT01621256 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution
Description: Day 1: Intravenous infusion; Days 2, 4, and 6: Subcutaneous injections
Study NCT04472481 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ergocalciferol 1.25 mg tablet
Description: weekly 50000 IU of Vitamin D2 (Ergocalciferol 1.25 mg tablet) given orally group II
Study NCT02406573 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Crest® Sensi-Stop™ Strips
Study NCT00978419 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: Loading dose 40mg by mouth first day, then 20 mg by mouth for up to 27 days
Study NCT00978419 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered every day for up to 28 days
Study NCT00633178 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group interpersonal therapy (IPT)
Description: Group IPT will include weekly treatment sessions with a psychiatrist for 12 weeks. The sessions will focus on overcoming relationship problems associated with depression. The first two and last sessions will be alone with the psychiatrist and the remaining sessions will be with a group of five to eight other pregnant women.
Study NCT00633178 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual (TAU)
Description: TAU will include referrals to outpatient treatment, which may include cognitive behavioral psychotherapy, insight-oriented psychotherapy, and/or antidepressant medication. TAU participants receiving psychotherapy will attend 12 weekly treatment sessions comparable to the IPT group sessions; treatment for TAU participants receiving medication for their depression may last longer than 12 weeks.
Study NCT02291783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTL0009936
Description: Single dose